脑心通胶囊联合依达拉奉治疗急性脑梗死58例临床研究

Clinical Study on Naoxintong Capsules Combined with Edaravone in the Treatment of Acute Cerebral Infarction in 58 Cases

目的探讨脑心通胶囊联合依达拉奉治疗急性脑梗死的临床疗效。方法将医院神经内科2016年收治的急性脑梗死患者116例随机分为对照组(单用依达拉奉治疗)及观察组(脑心通联合依达拉奉治疗),各58例。两组均治疗2周。结果观察组总有效率为72.41%,显著高于对照组的50.00%(P<0.05);两组患者治疗后白细胞介素8(IL-8)及超敏C反应蛋白(hs-CRP)水平均明显降低,游离三碘甲状腺原氨酸(FT_3)水平均明显升高,且观察组改变更显著(P<0.05);两组患者治疗后游离甲状腺素(FT4)及促甲状素激素(TSH)水平与治疗前比较无明显差异(P>0.05);两组患者治疗后美国国立卫生研究院卒中量表(NIHSS)评分均显著降低,日常生活活动能力量表(ADL)评分均明显提高(P<0.05),且观察组变化更明显(P<0.05);两组患者不良反应发生率相当(20.69%比27.59%,P>0.05)。结论脑心通胶囊联合依达拉奉治疗急性脑梗死疗效显著,且不增加不良反应发生率,能有效改善长期预后,其机制可能与减少炎性介质数目及增加FT_3水平有关。

Objective To investigate the clinical effect of Naoxintong Capsules combined with edaravone in the treatment of acute cerebral infarction. Methods Totally 116 patients with acute cerebral infarction admitted to the Department of Neurology in our hospital in 2016 were randomly divided into the control group（treated with edaravone alone） and the observation group（treated with Naoxintong Capsules combined with edaravone）,58 cases in each group. The two groups were treated for 2 weeks. Results The total effective rate of the observation group was 72.41% ,which was significantly higher than 50.00% of control group（P 〈 0. 05）. After treatment,the levels of IL- 8 and hs-CRP in the two groups were significantly decreased,while the levels of FT3 in the two groups were significantly increased,and the changes in the observation group was more significant（P 〈 0. 05）. After treatment,the levels of FT4 and TSH in the two groups were not significantly dirt）rent fi＇om those before treatment（P 〉 0.05）. After treatment,the scores of NIHSS in the two groups were significantly decreased,while the scores of ADL in the two groups were significantly increased,and the changes in the ob- servation group was more significant（P 〈 0. 05）. There was no significant dift）rence in the incidence rate of adverse reactions between the two groups（20.69% vs. 27.59%, P 〉 0. 05）. Conclusion Naoxintong Capsules combined with edaravone is eft）ctive in the treatment of acute cerebral infamtion without increasing the incidence of adverse reactions, which can eft）ctively improve the long- term prognosis. The mechanism may be related to the reduction of the number of inflammatory mediators and the increase of FT3 level.